Voloridge Investment Management
ACAD icon

Voloridge Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Voloridge Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-725,508
Closed -$13.3M – 1150
2024
Q4 		$13.3M Sell
725,508
-583,485
-45% -$9.42M 0.05% 490
2024
Q3 		$20.1M Sell
1,308,993
-292,223
-18% -$4.87M 0.07% 372
2024
Q2 		$26M Buy
1,601,216
+243,243
+18% +$3.93M 0.1% 291
2024
Q1 		$25.1M Buy
1,357,973
+75,796
+6% +$1.88M 0.09% 276
2023
Q4 		$40.1M Buy
1,282,177
+237,676
+23% +$5.68M 0.16% 175
2023
Q3 		$21.8M Buy
1,044,501
+529,927
+103% +$14.4M 0.11% 267
2023
Q2 		$12.3M Buy
514,574
+298,642
+138% +$6.64M 0.06% 408
2023
Q1 		$4.06M Sell
215,932
-289,172
-57% -$5.51M 0.02% 747
2022
Q4 		$8.04M Sell
505,104
-199,461
-28% -$3.12M 0.04% 501
2022
Q3 		$11.5M Sell
704,565
-337,690
-32% -$5.47M 0.06% 407
2022
Q2 		$14.7M Buy
1,042,255
+617,594
+145% +$11.5M 0.08% 336
2022
Q1 		$10.3M Buy
424,661
+98,748
+30% +$2.39M 0.06% 401
2021
Q4 		$7.61M Sell
325,913
-443,759
-58% -$8.93M 0.04% 551
2021
Q3 		$12.8M Buy
769,672
+169,240
+28% +$3.26M 0.08% 345
2021
Q2 		$14.6M Sell
600,432
-38,932
-6% -$879K 0.1% 263
2021
Q1 		$16.5M Buy
+639,364
New +$28.1M 0.12% 222
2019
Q4 		– Sell
-104,352
Closed -$3.76M – 1049
2019
Q3 		$3.76M Buy
104,352
+92,192
+758% +$2.8M 0.07% 315
2019
Q2 		$325K Sell
12,160
-21,618
-64% -$552K 0.01% 634
2019
Q1 		$907K Buy
+33,778
New +$789K 0.03% 508

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Voloridge Investment Management's ACAD Position: Q1 2025 in Review

Voloridge Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 725,508 shares — an estimated $13.3M sold.

Voloridge Investment Management first reported a position in ACAD in Q1 2019 and held it in 19 quarters. The position peaked at $40.1M in Q4 2023. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

  • Voloridge Investment Management reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 725,508 Acadia Pharmaceuticals shares in Q1 2025, an estimated $13.3M.
  • Voloridge Investment Management first reported a position in Acadia Pharmaceuticals in Q1 2019 and held it in 19 quarters.
  • Voloridge Investment Management's Acadia Pharmaceuticals position peaked at $40.1M in Q4 2023.
  • 320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Voloridge Investment Management's 13F filing for Q1 2025, filed 15 May 2025.